Revvity (NYSE:RVTY) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Revvity (NYSE:RVTY) to a strong-buy rating in a report issued on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Revvity’s Q2 2024 earnings at $1.15 EPS, Q3 2024 earnings at $1.19 EPS, Q4 2024 earnings at $1.33 EPS, FY2024 earnings at $4.65 EPS, Q1 2025 earnings at $1.10 EPS, Q2 2025 earnings at $1.28 EPS, Q3 2025 earnings at $1.35 EPS, Q4 2025 earnings at $1.52 EPS, FY2025 earnings at $5.25 EPS, Q1 2026 earnings at $1.24 EPS, Q2 2026 earnings at $1.44 EPS and FY2026 earnings at $5.84 EPS.

A number of other brokerages have also weighed in on RVTY. TD Cowen increased their target price on Revvity from $123.00 to $130.00 and gave the stock a buy rating in a research note on Tuesday, April 30th. Robert W. Baird raised their price objective on Revvity from $126.00 to $127.00 and gave the stock an outperform rating in a research note on Tuesday, April 30th. Barclays lowered their price objective on Revvity from $116.00 to $115.00 and set an equal weight rating on the stock in a research note on Friday, June 28th. SVB Leerink assumed coverage on Revvity in a research note on Monday. They set an outperform rating and a $125.00 price objective on the stock. Finally, Jefferies Financial Group assumed coverage on Revvity in a research note on Monday, June 3rd. They issued a hold rating and a $115.00 price target on the stock. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Revvity presently has an average rating of Moderate Buy and a consensus target price of $119.14.

Revvity Stock Performance

RVTY opened at $109.83 on Monday. Revvity has a 12-month low of $79.50 and a 12-month high of $131.96. The stock has a market cap of $13.55 billion, a price-to-earnings ratio of 90.75, a PEG ratio of 2.72 and a beta of 1.05. The business has a 50 day moving average of $107.32 and a 200-day moving average of $106.33. The company has a quick ratio of 1.92, a current ratio of 2.23 and a debt-to-equity ratio of 0.40.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Monday, April 29th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.04. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The company had revenue of $649.90 million during the quarter, compared to analysts’ expectations of $646.83 million. During the same period last year, the firm posted $1.01 earnings per share. The business’s revenue was down 3.7% on a year-over-year basis. On average, equities research analysts expect that Revvity will post 4.65 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Stockholders of record on Friday, July 19th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.25%. The ex-dividend date is Friday, July 19th. Revvity’s dividend payout ratio (DPR) is presently 23.14%.

Insider Transactions at Revvity

In other news, insider Joel S. Goldberg sold 4,000 shares of Revvity stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $110.46, for a total value of $441,840.00. Following the completion of the transaction, the insider now directly owns 36,900 shares of the company’s stock, valued at approximately $4,075,974. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Institutional Trading of Revvity

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust bought a new stake in Revvity during the 4th quarter worth approximately $25,000. Gladius Capital Management LP boosted its stake in shares of Revvity by 84.1% in the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after buying an additional 106 shares during the last quarter. Benjamin F. Edwards & Company Inc. purchased a new position in shares of Revvity in the 4th quarter worth approximately $27,000. CENTRAL TRUST Co purchased a new position in shares of Revvity in the 4th quarter worth approximately $27,000. Finally, ORG Partners LLC bought a new position in Revvity in the fourth quarter valued at $32,000. 86.65% of the stock is owned by institutional investors.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.